4//SEC Filing
Thomsen Jillian B. 4
Accession 0001209191-21-006211
CIK 0000906709other
Filed
Jan 28, 7:00 PM ET
Accepted
Jan 29, 6:10 PM ET
Size
13.4 KB
Accession
0001209191-21-006211
Insider Transaction Report
Form 4
Thomsen Jillian B.
VP & Chief Accounting Officer
Transactions
- Exercise/Conversion
Common Stock
2021-01-28$8.80/sh+37,500$330,000→ 251,257 total - Exercise/Conversion
Stock Option
2021-01-28−37,500→ 0 totalExercise: $8.80From: 2017-02-06Exp: 2021-02-05→ Common Stock (37,500 underlying) - Exercise/Conversion
Stock Option
2021-01-28−37,500→ 0 totalExercise: $8.80From: 2017-02-06Exp: 2021-02-05→ Common Stock (37,500 underlying) - Sale
Common Stock
2021-01-28$18.62/sh−75,000$1,396,500→ 176,257 total - Exercise/Conversion
Common Stock
2021-01-28$8.80/sh+37,500$330,000→ 213,757 total
Footnotes (3)
- [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021.
- [F2]This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 5,690 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c).
- [F3]This transaction was executed in multiple trades at prices ranging from $18.26 to $19.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
Documents
Issuer
NEKTAR THERAPEUTICS
CIK 0000906709
Entity typeother
Related Parties
1- filerCIK 0001433457
Filing Metadata
- Form type
- 4
- Filed
- Jan 28, 7:00 PM ET
- Accepted
- Jan 29, 6:10 PM ET
- Size
- 13.4 KB